Azithromycin for Critical Asthma - Pediatrics

Launched by JOHNS HOPKINS ALL CHILDREN'S HOSPITAL · Jan 16, 2024

Keywords

ClinConnect Summary

The CR-AZI Study is a clinical trial that is looking at how a medication called Azithromycin can help children with critical asthma. This study is specifically for kids aged 3 to 17 years who are receiving treatment in the Pediatric Intensive Care Unit (PICU) for severe asthma attacks. The trial aims to understand how Azithromycin affects the immune system in these young patients, with the hope that it may improve their condition during critical illness.

To participate in this study, children must have a primary diagnosis of critical asthma and be on certain treatments, such as continuous or intravenous beta-agonist therapy and intravenous corticosteroids. However, there are some exclusions, meaning certain children cannot join, like those with specific heart conditions or ongoing use of similar antibiotics. If eligible, participants can expect to receive Azithromycin along with their usual care, and their progress will be closely monitored by the medical team. This trial is currently recruiting participants, so it’s a good opportunity for families seeking additional treatment options for their child’s severe asthma.

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • Age 3-17 years
• • Admission to the PICU
• • Primary diagnosis of critical asthma
• • Prescription for continuous inhaled beta-agonist therapy and/or intravenous (IV) beta-agonist therapy
• • Prescription for intravenous systemic corticosteroids
• • Exclusion criteria
• • Critical Congenital Heart Disease Unrepaired
• • Tracheostomy Dependence at Admission
• • Ongoing Exposure to Azithromycin or Macrolide Antibiotics for any indication
• • Past Medical History of Prolonged QT Syndrome or Arrhythmias
• • Concomitant respiratory pathology including Acute Chest Syndrome, Interstitial Lung Disease, Cystic Fibrosis, and pulmonary hypertension